Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.

Ophthalmology - 1 Jan 2013

Abedi Farshad, Wickremasinghe Sanjeewa, Richardson Andrea J, Makalic Enes, Schmidt Daniel F, Sandhu Sukhpal S, Baird Paul N, Guymer Robyn H

Abstract excerpt

PURPOSE: To determine the association of genetic variants of the VEGFA gene with outcome of anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (AMD). DESIGN: A prospective cohort study. PARTICIPANTS: We included 201 consecutive patients receiving anti-VEGF injections for neovascular AMD. METHODS: Patients were followed over 12 months. They were treated with 3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Intravitreal Injections

Share to Sequence Tagged Sites

Share to Tomography, Optical Coherence

Share to Visual Acuity

Share to Wet Macular Degeneration

Source

Identifiers

PMID: 23149126
DOI: 10.1016/j.ophtha.2012.10.006

Genes

VEGFA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.PMID 23149126Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).Semantic proximity Read ↗

Common variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration.Semantic proximity Read ↗

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis.Semantic proximity Read ↗

VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration.Semantic proximity Read ↗

Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.Semantic proximity Read ↗

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.Semantic proximity Read ↗

Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.Semantic proximity Read ↗

Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.Semantic proximity Read ↗

Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.Semantic proximity Read ↗

Genetic markers of the effectiveness of anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.